Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2016

01-07-2016 | Preclinical study

Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer

Authors: Emma E. Bright, Keith J. Petrie, Ann H. Partridge, Annette L. Stanton

Published in: Breast Cancer Research and Treatment | Issue 2/2016

Login to get access

Abstract

The treatment of chronic illness, and the prevention of disease progression and recurrence, often involve long-term adherence to prescription medications in breast cancer. Despite the survival benefit of endocrine therapies, nonadherence remains high. In this study, we examined barriers to and facilitators of endocrine therapy adherence among women with breast cancer (n = 1371). Participants currently taking tamoxifen or aromatase inhibitors were recruited from Dr. Susan Love Research Foundation’s Army of Women® Registry. Participants responded online to open-ended and close-ended questions about thoughts, feelings, and behaviors relevant to endocrine therapy. Two weeks later, women were invited to complete a second online questionnaire regarding current endocrine therapy adherence. Approximately one-third (36 %) of participants reported the presence of factors that make endocrine therapy difficult; reporting any barrier to medication adherence was significantly associated with nonadherence (P < 0.001). In addition, 31 % of women used one or more strategies to maintain their motivation to adhere and the use of cognitive self-talk (e.g., thoughts regarding endocrine therapy efficacy) was related to higher adherence. Hierarchical linear regressions revealed a significant behavioral barrier × behavioral facilitator interaction (P < 0.05); participants who endorsed a behavioral barrier in the absence of a behavioral facilitator reported the lowest adherence. Findings suggest that a sizeable minority of women face barriers to taking endocrine therapy, which are associated with nonadherence.
Literature
1.
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Jemal A (2014) Cancer treatment and survivorship statistics, 2014. Cancer J Clin 64:252–271CrossRef
2.
Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6CrossRefPubMedPubMedCentral
3.
Burstein HJ, Temin S, Anderson H, Buchholz A, Davidson NE, Gelmon KE, Griggs JJ (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32:2255–2269CrossRefPubMedPubMedCentral
4.
McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Brit J Cancer 99:1763–1768CrossRefPubMedPubMedCentral
5.
Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Brit J Cancer 108:1515–1524CrossRefPubMedPubMedCentral
6.
Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Neuge AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Tr 126:529–537CrossRef
7.
Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Tr 134:459–478CrossRef
8.
Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602–606CrossRefPubMed
9.
Sedjo RL, Devine S (2011) Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Tr 125:191–200CrossRef
10.
Gadkari AS, McHorney CA (2010) Medication nonfulfillment rates and reasons: narrative systematic review. Curr Med Res Opin 26:683–705CrossRefPubMed
11.
Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii M, Chestnut J, Buist DSM (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8(6):149–157CrossRef
12.
Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherences beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97–102CrossRefPubMed
13.
Simon R, Latreille J, Matte C, Desjardins P, Bergeron E (2013) Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg 57(1):26–32CrossRef
14.
Harrow A, Dryden R, McCowan C, Radley A, Parsons M, Thompson AM, Wells M (2014) A hard pill to swallow: a qualitative study of women’s experience of adjuvant endocrine therapy for breast cancer. BMJ Open 4(6):e005285CrossRefPubMedPubMedCentral
15.
Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Tr 145:525–534CrossRef
16.
Odegard PS, Capoccia K (2007) Medication taking and diabetes: a systematic review of the literature. Diabetes Educator. 33(6):1014–1029CrossRefPubMed
17.
DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160(14):2101–2107CrossRefPubMed
18.
Gonzales JS, Batchelder A, Psaros C, Safren SA (2011) Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J AIDS 58(2):181–187
19.
Roberts KJ (2004) Barriers to and facilitators of HIV-positive patients’ adherence to antiretroviral treatment regimens. AIDS patient care and STDs 14(3):155–168CrossRef
20.
DiMatteo MR (2004) Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 23(2):207–218CrossRefPubMed
21.
Gierisch JM, Earp JA, Brewer NT, Rimer BK (2010) Longitudinal predictors of nonadherence to maintenance of mammography. Cancer Epidemiol Biomarkers Prev 19:1103–1111CrossRefPubMedPubMedCentral
22.
Stanton AL, Bernaards CA, Ganz PA (2005) The BCPT Symptom Scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer I 97:448–456CrossRef
23.
24.
Crites SL, Fabrigar LR, Petty RE (1994) Measuring the affective and cognitive properties of attitudes: conceptual and methodological issues. Pers Soc Psychol B 20:619–634CrossRef
25.
Tracey TJ, Kokotovic AM (1989) Factor structure of the working alliance inventory. Psychol Assess 1:207–210CrossRef
26.
Horvath AO, Greenberg LS (1989) Development and validation of the working alliance inventory. J Couns Psychol 36:223–233CrossRef
27.
Busseri MA, Tyler JD (2003) Interchangeability of the working alliance inventory and working alliance inventory, short form. Psychol Assess 15:193–197CrossRefPubMed
28.
Haynes RB, Sackett DL (1979) Compliance in health care. Johns Hopkins University Press, Baltimore
29.
DiMatteo MR (2004) Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 42(3):200–209CrossRefPubMed
30.
Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45:431–439CrossRefPubMed
31.
Carpenter CJ (2010) A meta-analysis of the effectiveness of health belief model variables in predicting behavior. Health Commun 25(8):661–669CrossRefPubMed
32.
Ajzen I (1991) The theory of planned behavior. Org Behav Human Dec Process 50:179–211CrossRef
33.
Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67–74CrossRefPubMed
34.
Lavsa SM, Holzworth A, Ansani NT (2011) Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc 51:90–94CrossRef
35.
Garber MC, Nau DP, Erickson SR, Aikens JE, Lawerence JB (2004) The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 42(7):649–652CrossRefPubMed
36.
Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Tr 137:829–836CrossRef
37.
Ruddy K, Mayer E, Partridge AH (2009) Patients adherence and persistence with oral anticancer treatment. CA-Cancer J Clin 59:56–66CrossRefPubMed
38.
Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(26):556–562CrossRefPubMed
39.
Fisher B, Constantino JP, Wickerharn DL, Redmond CK, Kavanah M, Cronin WM, Wolmark N (1998) Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and bowel project P-1 study. J Natl Cancer I 90:1371–1388CrossRef
Metadata
Title
Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer
Authors
Emma E. Bright
Keith J. Petrie
Ann H. Partridge
Annette L. Stanton
Publication date
01-07-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3871-3

Other articles of this Issue 2/2016

Breast Cancer Research and Treatment 2/2016 Go to the issue

Epidemiology

Ages at menarche- and menopause-related genetic variants in relation to terminal duct lobular unit involution in normal breast tissue

Preclinical study

Amount of stroma is associated with mammographic density and stromal expression of oestrogen receptor in normal breast tissues

Epidemiology

The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer

Review

Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications

Epidemiology

Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer

Epidemiology

Axillary evaluation and lymphedema in women with ductal carcinoma in situ
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits